利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.025 秒)

    Assay for Prions
    2.
    发明申请
    Assay for Prions 审中-公开
    朊病毒检测

    公开(公告)号：US20130196356A1

    公开(公告)日：2013-08-01

    申请号：US13824307

    申请日：2011-09-13

    申请人： Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

    发明人： Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6896 ,  G01N33/6893 ,  G01N2333/70596 ,  G01N2800/2828

    摘要： The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.

    摘要翻译： 本发明涉及一种用于检测血液或尿样品中异常PrP的方法，所述方法包括：（a）用缓冲液稀释样品以包含（i）10mM至500mM缓冲剂的终浓度; （ii）1％至10％w / v牛血清白蛋白; 和（iii）1％至8％w / v CHAPS; （b）加入钢颗粒并孵育以允许PrP结合; （c）洗涤钢颗粒以除去稀释的样品; 和（d）使用能够结合所述异常PrP的抗体检测在钢颗粒上捕获的异常PrP。 本发明还提供组合物和试剂盒。

    Split Cycle Reciprocating Piston Engine
    4.
    发明申请
    Split Cycle Reciprocating Piston Engine 有权
    分体循环往复式活塞发动机

    公开(公告)号：US20120103314A1

    公开(公告)日：2012-05-03

    申请号：US13133765

    申请日：2009-12-11

    申请人： Neville Stuart Jackson ,  Andrew Farquhar Atkins

    发明人： Neville Stuart Jackson ,  Andrew Farquhar Atkins

    IPC分类号： F02B33/22 ,  F02M25/00

    CPC分类号： F02B41/06 ,  F02B29/0406 ,  F02B43/10 ,  F02B47/02 ,  F02B47/04 ,  F02M25/00 ,  F02M25/03 ,  Y02T10/121 ,  Y02T10/32

    摘要： A split cycle reciprocating piston engine includes a compression cylinder (2) accommodating a compression piston (4) and an expansion cylinder (12) accommodating an expansion piston (14). The compression cylinder (2) has an inlet port (30) for the admission of air and an outlet port (36) which communicates with a first path of a heat exchanger (5). The expansion cylinder (12) has an inlet port (52), which communicates with the first path of the heat exchanger (5), and an outlet port (56), which communicates with a second path of the heat exchanger (5) in heat exchange relationship with the first path. The method of operating the engine includes injecting a liquefied, non-oxidising, non-combustible gas, such as nitrogen, into the compression cylinder (2).

    摘要翻译： 分流式往复活塞式发动机包括容纳压缩活塞（4）的压缩气缸（2）和容纳膨胀活塞（14）的膨胀气缸（12）。 压缩缸（2）具有用于容纳空气的入口（30）和与热交换器（5）的第一路径连通的出口（36）。 膨胀气缸（12）具有与热交换器（5）的第一路径连通的入口（52）和与热交换器（5）的第二路径连通的出口（56） 与第一条路线的热交换关系。 操作发动机的方法包括将液化的，非氧化的不可燃气体（例如氮气）喷射到压缩气缸（2）中。

    Device and method for transcutaneous surgery
    5.
    发明授权
    Device and method for transcutaneous surgery 失效
    经皮手术的装置和方法

    公开(公告)号：US6074380A

    公开(公告)日：2000-06-13

    申请号：US37087

    申请日：1998-03-09

    申请人： Phillip Owen Byrne ,  Thomas Stuart Jackson Elliott

    发明人： Phillip Owen Byrne ,  Thomas Stuart Jackson Elliott

    IPC分类号： A61M25/00 ,  A61B19/00 ,  A61M25/01 ,  A61M5/32

    CPC分类号： A61M25/0111 ,  A61B90/40

    摘要： This invention relates to a device and method for use in transcutaneous surgical procedures, such as transcutaneous catheterization and surgical biopsy.To provide that the operative parts of instrumentation to be introduced into the patient's body are shielded from contact with the patient's skin, and thereby to inhibit transfer of micro-organisms from the skin into the body, there is provided a transcutaneous indwelling shield device for insertion into a skin aperture, comprising a transcutaneous distal portion providing an instrument access port, connecting to a proximal portion of shallow dished form of substantially greater dimension than said access port, the proximal portion tapering inwardly to said distal portion to readily guide the distal tip of the instrument to said access port. The distal portion serves as a wound retractor, and to this end at least the distal portion may be of resilient form to be resiliently deformed from a first, relatively open, configuration to a second, relatively closed, configuration.The invention has particular application in the field of central venous catheterization.

    摘要翻译： 本发明涉及一种用于经皮外科手术的装置和方法，例如经皮导管插入术和外科活检。 为了提供要引入患者身体的仪器的操作部分被屏蔽以免与患者皮肤接触，从而抑制微生物从皮肤转移到体内，提供了一种用于插入的经皮留置屏蔽装置 进入皮肤孔，包括提供仪器进入口的经皮远端部分，其连接到比所述进入口大致更大尺寸的浅盘形形状的近端部分，所述近端部分向内渐缩到所述远端部分，以便容易地将所述远端部分 仪器到达所述进入端口。 远侧部分用作缠绕的牵开器，并且为此，至少远端部分可以是弹性形式，以从第一相对开放的构造弹性变形到第二相对封闭的构型。 本发明在中心静脉导管插入术中具有特殊应用。

    Trailing link suspension for a bicycle
    6.
    发明授权
    Trailing link suspension for a bicycle 有权

    公开(公告)号：US11801911B1

    公开(公告)日：2023-10-31

    申请号：US17887207

    申请日：2022-08-12

    申请人： Stuart Jackson Consulting, LLC

    发明人： Stuart Jackson

    IPC分类号： B62K25/16

    CPC分类号： B62K25/16 ,  B62K2201/00

    摘要： A trailing link suspension for a bicycle includes at least one fork arm. The fork arm including a proximal end and a distal end defining a non-linear portion disposed between generally straight portions such that the distal end is at an angle of approximately 70°˜90° relative to the proximal end. The fork arm is rotatably fixed to a bicycle frame. The suspension includes a shock absorber comprising a first end and a second end, defining a length therebetween. The first end of the shock absorber rotatably fixed to the non-linear portion. The suspension includes a link including a first end and a second end defining a length therebetween. The second end of the shock absorber is rotatably fixed to the link, the first end of the link fixed to the second end of the fork arm and the second end of the link fixed to an axle.

    Diagnosis of neurodegenerative diseases
    7.
    发明授权
    Diagnosis of neurodegenerative diseases 有权
    诊断神经退行性疾病

    公开(公告)号：US09028801B2

    公开(公告)日：2015-05-12

    申请号：US11792686

    申请日：2005-12-07

    申请人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

    发明人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

    IPC分类号： A61B5/145 ,  G01N33/48 ,  C07K14/805 ,  C07K14/75 ,  C07K14/705 ,  G01N33/68

    CPC分类号： G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

    摘要： The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

    摘要翻译： 本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比， 蛋白质是：β-肌动蛋白（SwissProt Acc.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Acc。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Acc。编号P01009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。 补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Acc。No. P51884）; α-纤维蛋白原前体（SwissProt Acc。编号P02671）; IGHG4蛋白（Swiss Prot Acc。No.Q8TC63）或免疫球蛋白λ重链。 还公开了其它标记蛋白。

    Diagnosis of Neurodegenerative Diseases
    8.
    发明申请
    Diagnosis of Neurodegenerative Diseases 有权
    诊断神经退行性疾病

    公开(公告)号：US20080213802A1

    公开(公告)日：2008-09-04

    申请号：US11792686

    申请日：2005-12-07

    申请人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

    发明人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

    IPC分类号： G01N33/53 ,  C12Q1/02 ,  C12Q1/46

    CPC分类号： G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

    摘要： The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

    摘要翻译： 本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比， 蛋白质是：β-肌动蛋白（SwissProt Ace.No.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Ace。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Ace.Po1009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。 补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Ace。No. P51884）; α-纤维蛋白原前体（SwissProt Ace。编号P02671）; IGHG4蛋白（Swiss Prot Ace。No.Q8TC63）或免疫球蛋白λ重链。 还公开了其它标记蛋白。